Does Cigna Cover Ozempic? Express Scripts, PA Criteria, and the Appeal Math

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited

As of May 2026. Confirm directly with your plan. Insurance coverage varies by employer plan, region, and time. Always confirm with your specific plan administrator.

Key Takeaways

• Cigna commercial plans typically cover Ozempic for type 2 diabetes through Express Scripts PA, with the drug on a preferred or non-preferred brand tier depending on plan
• Express Scripts is owned by Evernorth Health Services, Cigna's parent-side subsidiary, so the PBM and insurer share an integrated workflow
• Cigna does not cover Ozempic for weight loss. Wegovy or Zepbound is the path when the plan includes weight-loss drug coverage
• Step therapy is common on Cigna plans. Trulicity, Bydureon BCise, or another preferred agent may be required first
• Cigna's denial letters are detailed. The reason cited tells you exactly what to attack on appeal

Direct answer

Cigna typically covers Ozempic for adults with type 2 diabetes when Express Scripts approves the prior authorization. The PA requires the T2D diagnosis and, on most plans, a prior metformin trial. As of May 2026, weight-loss use is not covered. Coverage and tier placement vary by specific Cigna plan and by the employer benefit design layered on top.

Table of contents

1. The Cigna and Express Scripts relationship
2. Cigna formularies and where Ozempic sits
3. Express Scripts PA criteria, written plainly
4. Step therapy: when Cigna wants another GLP-1 first
5. Reading the Cigna denial letter
6. How to build a Cigna appeal that gets reviewed seriously
7. External review and the state insurance department path
8. Cigna Medicare Advantage and Part D differences
9. Employer plan layering: same Cigna card, different rules
10. Cost-sharing examples across Cigna plan types
11. When Cigna says no permanently: 503A compounded as an alternative
12. Contrary view: the case for stricter PA
13. Decision framework
14. FAQ
15. Sources

The Cigna and Express Scripts relationship

Cigna acquired Express Scripts in 2018, and the PBM now operates under the Evernorth Health Services umbrella alongside Accredo (specialty pharmacy) and other Cigna-owned health services. The integration matters for pharmacy claims processing: Express Scripts is the PBM that runs the Cigna formulary, processes prescription claims, and adjudicates PAs.

This vertical structure resembles the UnitedHealthcare and OptumRx relationship. Decisions about Ozempic coverage come from Express Scripts pharmacists working off Cigna's formulary policy. Customer service routing depends on whether your question is about plan benefits (Cigna) or pharmacy claim handling (Express Scripts).

Cigna formularies and where Ozempic sits

Cigna uses several commercial formularies. The most common in employer-sponsored plans are the Standard formulary and the Performance formulary. Both place Ozempic on the preferred brand tier as of May 2026, though the cost-sharing structure differs.

Cigna plan formulary	Ozempic tier	Typical patient cost
Standard 4-tier	Tier 2 preferred brand	$45 to $90 copay
Performance 4-tier	Tier 2 preferred brand	$50 to $100 copay
Value 3-tier	Tier 3 non-preferred brand	$80 to $150 copay
HDHP plans	Tier 2 or 3	Full cost before deductible
Cigna MA-PD Part D	Preferred or non-preferred	$45 to $100 initial coverage

Express Scripts PA criteria, written plainly

Cigna's Ozempic PA, administered by Express Scripts, asks a short clinical checklist:

• Diagnosis. Type 2 diabetes documented in the chart (ICD-10 E11.x). Prediabetes does not qualify. Type 1 diabetes does not qualify.
• Age. 18 or older.
• Prior therapy. Trial of metformin at maximum tolerated dose for at least 90 days, or documented contraindication. Common contraindications: eGFR less than 30, lactic acidosis history, severe hepatic impairment.
• A1c. Recent A1c value documented. Some plans require A1c above 6.5% or 7.0% for initial approval.
• Step therapy where applicable. Prior trial of the preferred GLP-1 documented, or clinical reason to bypass.
• Indication match. Prescription is for FDA-labeled indications (glycemic control in T2D, or cardiovascular risk reduction in T2D with established ASCVD).

Approvals are typically issued for 12 months. Renewal requires the prescriber to attest continued benefit.

Step therapy: when Cigna wants another GLP-1 first

Cigna applies step therapy on many commercial plans for GLP-1 agonists. The preferred drug shifts with manufacturer negotiations, but Trulicity and Bydureon BCise have been common preferred steps. As of May 2026, some Cigna plans have shifted preference toward Mounjaro for T2D given its strong clinical data in head-to-head with semaglutide.

Step-therapy exceptions are available. The strongest grounds are documented prior trial of the preferred drug, intolerance, contraindication, or a clinical reason the prescriber documents specifically for the patient.

Reading the Cigna denial letter

Express Scripts denial letters for Cigna claims are structured. The reason category appears on the first page. Common categories:

• "Not covered for the requested indication." Weight-loss prescription, or T2D not documented. Limited appeal options.
• "Prior authorization required." PA not submitted or not yet processed. Fix is procedural.
• "Step therapy required." A preferred GLP-1 has not been tried. Fix is exception request with clinical justification.
• "Documentation does not support medical necessity." PA filed but missing key elements. Fix is resubmission with complete documentation.
• "Plan benefit does not cover this medication." Employer exclusion. No internal appeal will overturn an exclusion.

How to build a Cigna appeal that gets reviewed seriously

Cigna appeals are adjudicated by Express Scripts clinical pharmacists or, on second-level review, by medical directors. Quality of documentation determines outcomes.

A strong Cigna appeal letter from the prescriber covers, in order:

1. The diagnosis with ICD-10 code, supported by chart notes
2. The full treatment history, with metformin dates, doses, durations, and outcomes
3. Step-therapy history if applicable, including prior GLP-1 trials with specific reasons for discontinuation
4. The clinical rationale for Ozempic specifically, tied to the patient's profile
5. The plan's coverage criteria addressed line by line
6. A clear request for overturn and the requested approval duration

Internal appeals decide within 30 days for standard requests. Expedited appeals, available when delay would jeopardize health, decide within 72 hours.

External review and the state insurance department path

If Cigna upholds the denial on internal appeal, external review applies under ACA Section 2719. The reviewer is an independent physician with relevant specialty experience. The decision is binding on Cigna.

The deadline is typically 4 months from the final internal denial. The form arrives with the final denial letter. Decisions arrive within 45 days for standard requests, 72 hours for expedited.

State variation matters. New York, California, and several other states run their own external review processes. Other states use federally-accredited Independent Review Organizations contracted through HHS. The Cigna denial letter will direct you to the right path for your state.

Cigna Medicare Advantage and Part D differences

Cigna Healthspring Medicare Advantage plans with Part D (MA-PD) cover Ozempic for type 2 diabetes. The coverage tracks federal Part D rules rather than the commercial Cigna formulary.

Key Medicare differences:

• The Novo Nordisk manufacturer card is not available to Medicare beneficiaries due to the federal anti-kickback statute
• The 2025 Part D out-of-pocket cap of $2,000 per year applies
• Weight-loss coverage is excluded by Part D statute. The November 2024 CMS rule allows GLP-1 coverage for cardiovascular indication when prescribed for that purpose (relevant for Wegovy under the SELECT CV indication)
• Appeals follow the Part D Coverage Determination, Redetermination, Independent Review Entity, and Administrative Law Judge pathway

Employer plan layering: same Cigna card, different rules

Cigna services many self-funded employer plans. The employer sets the benefit design. Two Cigna cards from two employers can produce two different coverage outcomes for the same drug.

Specific layering possibilities:

• Some employer plans exclude all weight-loss drugs
• Some carve out GLP-1 agonists specifically
• Some require BMI thresholds even for T2D use
• Some set quantity limits below FDA-approved dosing
• Some require additional documentation beyond Express Scripts' standard PA

Your Summary of Benefits and Coverage and Evidence of Coverage documents are authoritative on what your specific plan covers.

Cost-sharing examples across Cigna plan types

Scenario	Approximate monthly cost
Cigna Standard, Tier 2, PA approved, with manufacturer card	$25
Cigna Standard, Tier 2, PA approved, no card	$45 to $90
Cigna Performance, Tier 2	$50 to $100
Cigna Value, Tier 3	$80 to $150
Cigna HDHP before deductible	$900 to $1,000
Cigna MA-PD initial coverage	$45 to $100, up to $2,000 OOP cap
Cash without insurance	$950 to $1,100

When Cigna says no permanently: 503A compounded as an alternative

If Cigna denies coverage through internal appeal and external review, brand-name routes narrow to the Novo Nordisk patient assistance program (income-qualified) or cash pricing. For patients who cannot use either, 503A compounded semaglutide via telehealth is a path worth understanding.

FormBlends works with state-licensed 503A pharmacies and licensed clinicians. The product is individually compounded for each patient based on a prescription. Compounded semaglutide is not FDA-approved and is not equivalent to brand-name Ozempic, despite the same active molecule. The regulatory pathway and supply chain differ.

The decision belongs with the patient and clinician. For some Cigna members who have failed coverage routes and cannot absorb brand-name cash pricing, 503A compounded is a reasonable bridge. For others, the patient assistance program is the better fit.

Contrary view: the case for stricter PA

Cigna's PA criteria look strict to patients. They look reasonable in a market where GLP-1 demand has stretched supply and where off-label prescribing has been documented in patient populations the FDA labeling does not address. Step therapy in particular has a defense: dulaglutide and tirzepatide work; many patients tolerate the preferred drug; the plan-level economics on Ozempic are not always favorable.

The counterargument is that PA is a friction tax that delays care without changing the eventual prescribing decision in many cases. Studies on PA approval rates for GLP-1 agonists show high eventual approval rates after appeals, raising the question of whether the upfront denial serves a clinical purpose or just a delay function. Reasonable people disagree.

Decision framework

If you have T2D and Cigna commercial: file the PA. Document metformin trial and step therapy as applicable. Appeal denials with the specific reason as the target.

For weight loss: Ozempic is not the right ask. Pivot to Wegovy or Zepbound where coverage exists.

If your Cigna plan excludes weight-loss drugs: internal appeal will not overturn an exclusion. Look at patient assistance, alternative coverage, or 503A.

If you are on Cigna MA-PD: coverage for T2D applies with the $2,000 OOP cap. No manufacturer card.

FAQ

Does Cigna cover Ozempic? For T2D yes, via Express Scripts PA. For weight loss no.

Is Express Scripts Cigna? Express Scripts is the Cigna-owned PBM under Evernorth. They share an integrated workflow.

What's the PA criteria? T2D, age 18+, prior metformin trial, sometimes step therapy.

Why was I denied? Most common: weight-loss indication, missing PA, step therapy not satisfied, employer exclusion.

How do I appeal? File with Cigna or Express Scripts within the deadline. Build the file around the specific denial reason.

Does Cigna MA-PD cover it? For T2D yes. Weight loss no. New $2,000 OOP cap applies.

What if appeal fails? External review under the ACA. Manufacturer assistance, alternative drugs, or 503A compounded.

Sources

1. Cigna commercial formulary documents (Standard, Performance, Value). 2026.
2. Express Scripts clinical policy: GLP-1 receptor agonists. 2026.
3. Cigna Evernorth Health Services overview. 2026.
4. Centers for Medicare and Medicaid Services. Part D rules. 2026.
5. CMS Final Rule on Part D coverage of GLP-1 for cardiovascular indications. November 2024.
6. U.S. Food and Drug Administration. Ozempic prescribing information.
7. Marso SP, et al. SUSTAIN-6 cardiovascular outcomes. NEJM. 2016;375:1834-1844.
8. Affordable Care Act, Section 2719 external review.
9. American Diabetes Association. Standards of Care 2026.
10. Novo Nordisk. Ozempic Savings Card program terms.
11. U.S. Food and Drug Administration. 503A compounding regulations.

Footer disclaimers

Platform Disclaimer. FormBlends is a telehealth platform. We connect patients with licensed clinicians and do not adjudicate insurance claims. Information about Cigna policies reflects publicly available materials as of May 2026 and is subject to change.

Compounded Medication Notice. Compounded semaglutide is prepared by a state-licensed 503A pharmacy on an individual prescription basis. It is not FDA-approved, is not equivalent to brand-name Ozempic, and should be considered with a prescribing clinician's input.

Results Disclaimer. Coverage outcomes vary based on specific plan rules, documentation, and clinical situation. Cost-sharing examples are approximations.

Trademark Notice. Cigna and Evernorth Health Services are registered trademarks of The Cigna Group. Express Scripts is a registered trademark of Express Scripts Holding Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Trulicity, Mounjaro, and Zepbound are registered trademarks of Eli Lilly and Company. Bydureon is a registered trademark of AstraZeneca. FormBlends is not affiliated with these companies.